Asuragen launches KRAS, BRAF mutational testing in CLIA laboratory

Asuragen, Inc., a leader in molecular diagnostics and nucleic acid-based pharmacogenomics services, announced today that it has launched KRAS and BRAF mutational testing services in its CAP-accredited CLIA laboratory. Asuragen's KRAS and BRAF laboratory developed tests (LDTs) were designed in response to newly modified guidelines from the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN). Asuragen's KRAS and BRAF tests are intended to be used and interpreted in conjunction with all other available clinical and diagnostic information when evaluating anti-EGFR treatment options for colorectal cancer (CRC) patients. The tests are available in various configurations based on the patient's need or the clinical trial objective. The KRAS 7 Mutation testing service allows for detection of the seven clinically relevant KRAS mutations in codons 12 and 13 and the KRAS 12 Mutation test configuration expands the KRAS 7 test to detect an additional five KRAS mutations in codon 13.

“In addition, our CLIA laboratory provides our pharmaceutical and biotech partners with the full complement of assay development services and regulated testing facilities.”

"Adding KRAS and BRAF mutational testing to our CLIA laboratory menu further expands our mission in bringing personalized medicine solutions to our partners and patients," said Carol Berry, Vice President and General Manager of Asuragen's Pharmacogenomics Services. "In addition, our CLIA laboratory provides our pharmaceutical and biotech partners with the full complement of assay development services and regulated testing facilities."